View in web browser  |  Add to safe senders list
PR Week Follow us:
US Healthcare Newsletter  |  September 1st 2015

Abbott Laboratories has refuted rumors that it is trying to buy St. Jude Medical, Inc., Reuters reported Thursday morning. According to Reuters, The Financial Times ran the original article “citing people familiar with the matter” that the deal could be worth at least $25 billion.

The Star Tribune reported both companies’ stocks were boosted by the news. It also reported that a spokesperson for St. Jude would not confirm the news.

St. Jude made a deal worth $3.4 billion in cash in July to acquire Thoratec Corp., according to Bloomberg, and already has “an alliance” with Abbott “to sell their portfolio of cardiovascular products jointly to hospitals.”


In other news:

1. How Bayer is encouraging prostate cancer victims to 'Speak Up'
2. Experts: Sprout needs to show Addyi is not Viagra for women
3. Astellas moves the ball on prostate cancer awareness with #pass4prostate
4. Porter Novelli adds Catherine Fink to health and wellness practice as EVP

Top jobs of the month

To post a job on click here.

PRWeek Careers brings you : the best industry resource for landing your next career move. delivers career-related news, expert advice, and the latest job openings in the industry. Upload your resume today and start taking advantage of all that has to offer.


Manage Bulletins Unsubscribe